Table 3.
Pre-procedural Imaging Characteristics between Responders and Non-responders.
| Responder (n = 50) | Non-responder (n = 36) | P value | |
|---|---|---|---|
| Sorafenib usage | 13 (32.5%) | 5 (20.8%) | 0.312 |
| Pre-procedural Imaging Characteristics | |||
| APHE | 0.982 | ||
| Absent | 14 (28.0%) | 10 (27.8%) | |
| Present | 36 (72.0%) | 26 (72.2%) | |
| Washout on portal venous phase | 0.400 | ||
| Absent | 10 (20.0%) | 10 (27.8%) | |
| Present | 40 (80.0%) | 26 (72.2%) | |
| Capsule | 0.421 | ||
| Absent | 35 (70.0%) | 28 (77.8%) | |
| Present | 15 (30.0%) | 8 (22.2%) | |
| Tumor morphology | 0.063 | ||
| Well-defined | 41 (82.0%) | 23 (63.9%) | |
| Infiltrative | 9 (18.0%) | 13 (36.1%) | |
| Cystic degeneration | 0.657 | ||
| Absent | 31 (62.0%) | 24 (66.7%) | |
| Present | 19 (38.0%) | 12 (33.3%) | |
| Macroscopic vessel involvement | 0.595 | ||
| Absent | 14 (28.0%) | 12 (33.3%) | |
| Present | 36 (72.0%) | 24 (66.7%) | |
| Exophytic growth | 0.803 | ||
| Absent | 40 (80.0%) | 28 (77.8%) | |
| Present | 10 (20.0%) | 8 (22.2%) | |
| Intra-hepatic vascular shunt | 0.004* | ||
| Absent | 35 (70.0%) | 14 (38.9%) | |
| Present | 15 (30.0%) | 22 (61.1%) | |
| Angiographic Characteristics | |||
| Feeding artery diameter | 0.865 | ||
| ≤microcatheter | 9 (18.0%) | 7 (19.4%) | |
| >microcatheter | 41 (82.0%) | 29 (80.6%) | |
| Number of supplying artery* | 0.934 | ||
| Single | 42 (84.0%) | 30 (83.3%) | |
| Multiple | 8 (16.0%) | 6 (16.7%) | |
| Vascular lake phenomenon (VLP) | 0.037* | ||
| Absent | 35 (70.0%) | 32 (88.9%) | |
| Present | 15 (30.0%) | 4 (11.1%) | |
| HTE on CBCT | <0.001* | ||
| Yes | 40 (80.0%) | 6 (16.7%) | |
| No | 10 (20.0%) | 30 (83.3%) | |
| Residual tumor blush | <0.001* | ||
| No | 28 (56.0%) | 3 (8.3%) | |
| Yes | 22 (44.0%) | 33 (91.7%) | |
| Sub-stasis endpoint | 0.720 | ||
| No | 4 (8.0%) | 5 (13.9%) | |
| Yes | 46 (92.0%) | 31 (86.1%) | |
Data are expressed as number of target lesions(percentage). P values derived from the chi-square test are significant (P < 0.05*) HTE: homogeneous tumor enhancement; CBCT: cone-beam CT; DEM-TACE: Drug-eluting transarterial chemoembolization.